What is CJC-1295 No DAC?

What sources report

What it is

Mod GRF 1-29 starts from GHRH(1-29), the first 29 of the 44 amino acids in human growth hormone-releasing hormone and the part that carries its full activity.¹ Four positions are changed: alanine 2 becomes D-alanine, asparagine 8 becomes glutamine, glycine 15 becomes alanine and methionine 27 becomes leucine.¹ Citing the developers, FDA says the swaps at 8 and 27 were meant to prevent chemical breakdown and oxidation, and D-alanine 2 is linked to resistance to DPP-IV, the main blood enzyme that inactivates GHRH(1-29); how much each swap adds to stability remains to be determined.¹ By FDA's reading, the form without the DAC first appears in a 2010 report on a preparation seized by Norwegian police and customs in 2009.¹⁴¹

How it is meant to work

GHRH binds receptors on somatotroph cells in the front (anterior) pituitary, which then release growth hormone; growth hormone in turn raises IGF-1.¹² CJC-1295 forms are designed to act the same way, but FDA found no study showing whether the form without DAC is pharmacologically active.¹² Claims that it releases growth hormone in natural pulses are extrapolated from related compounds, mainly sermorelin.² In 12 healthy men, one dose of the DAC form left pulse frequency and size unchanged while trough growth hormone rose 7.5-fold.⁹

What the human evidence covers

No published study has given Mod GRF 1-29 to people; FDA's 2024 review found no human, pharmacokinetic or toxicity studies of either form.¹² The human figures often quoted come from 63 healthy adults given CJC-1295 with DAC in studies published from 2006 to 2009, most of them after a single dose.¹² One injection of the DAC form lifted average growth hormone two- to tenfold for at least 6 days and IGF-1 1.5- to threefold for 9 to 11 days, but those are hormone levels, not health outcomes.⁵

What has not been shown

• Muscle: no study has measured muscle in people given either form.¹ A 2026 primer credits CJC-1295 plus ipamorelin with stronger muscles in rodents,¹⁰ but the 2001 rat study with that result gave ipamorelin alone.²⁶ See Peptides and muscle growth.
• Fat loss: none shown in people. Tesamorelin, a different GHRH analog, is FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy, a result that cannot be assumed for Mod GRF 1-29.²⁴¹² See Peptides and weight loss.
• Healing and recovery: a 2026 scoping review of six emerging peptides, CJC-1295 among them, found 67% of publications were animal studies and judged musculoskeletal benefits unsubstantiated in humans.¹¹ See Peptides and healing and recovery.
• Sleep, skin, hair and memory: these are website claims listed in FDA's review, untested for any CJC-1295 form.¹ See Peptides and sleep, Peptides and skin and hair and Peptides and focus and memory.
• Sexual health: growth hormone secretagogues raise growth hormone and IGF-1, but evidence for better sexual function is limited, and Mod GRF 1-29 is untested for testosterone or libido.¹²¹ See Peptides and men's health and Peptides and testosterone.
• Women: 87% of the people in the DAC-form studies were men.¹ See Peptides and women's health.
• Blood sugar: growth hormone labels warn of glucose intolerance and diabetes, and FDA says no data show CJC-1295 avoids that risk.¹ See Peptides and blood sugar.

Identity and product quality

FDA lists CAS 446036-97-1 for the free base and calls 863288-34-0 a deleted number; 446262-90-4 belongs to the DAC form.¹¹³ PubChem's record CID 56841945 mixes "with DAC" and "no DAC" labels in its synonyms.¹³ FDA found that research-use sellers did not state whether their CJC-1295 was the free base, acetate or TFA form, and powders seized in Denmark held versions of modified GRF 1-29 with an extra glycine at the front.¹¹⁵ Two 2026 reviews raise product quality concerns, and one calls CJC-1295 investigational.²⁵¹²

How it compares

A 2026 review grades the human evidence: tier A for tesamorelin, tier B for the DAC form and tier D, its lowest, for Mod GRF 1-29, which has no peer-reviewed human studies.² Related profiles: What is Tesamorelin? and What is Ipamorelin?. The research vial is listed as CJC-1295 No DAC for sale.

Side effects

No published study has reported side effects of Mod GRF 1-29 in people.¹² The nearest data come from small phase 1 trials of the longer-lasting DAC form in healthy adults:¹²

FDA lists increased heart rate and systemic vasodilatory reaction among serious adverse events associated with CJC-1295.¹⁶ Per anecdotal reports FDA cites, in ConjuChem's phase 2 trial in HIV lipodystrophy, a participant had a heart attack 2 hours after an 11th weekly dose of the DAC form and died about an hour later; the attending physician suspected underlying coronary artery disease.¹ The trial is listed as terminated, and its data were never published.¹⁷¹

Warnings

• Immune reactions: FDA says injected peptides like CJC-1295 may provoke immune responses, more so with aggregates and impurities; at 86% identical to natural GHRH, antibodies could also react with the body's own hormone.¹¹⁶
• Growth hormone effects: FDA says no data show CJC-1295 avoids the risks on growth hormone labels, including tumors, glucose intolerance, raised pressure inside the skull, fluid retention and pancreatitis.¹
• Tumors: FDA found no carcinogenicity study of any CJC-1295 form, and mice engineered to overproduce human GHRH develop pituitary overgrowth and tumors; a 2026 review calls the concern theoretical.¹²
• Heart and falls: FDA says faster heart rate, low blood pressure, dizziness and loss of coordination warrant study in people with heart disease or at risk of falls; long-term safety is unknown, with no data in children.¹
• Animal findings (DAC form): repeated injections caused minimal to mild injection-site bleeding, inflammation and tissue death in rats and dogs.¹
• Class effects: a 2026 review of growth hormone axis peptides lists prolactin and cortisol rises, appetite changes, blood sugar problems, fluid retention and muscle or joint aches.²

General precautions are in Peptide safety basics.

Dosage information

No human dose of CJC-1295 No DAC is established. No published human or animal study of this form reports a dose, and amounts circulating online come from websites and bodybuilding forums, not trials.¹² A 2026 sports medicine primer likewise lists dosing, frequency and duration for these peptides as unknown.¹⁰

The only published doses belong to CJC-1295 with DAC, and FDA says DAC results cannot be extrapolated to the form without it.¹ They show what was studied, not guidance for anyone:

Peptide dosage basics explains how to read study doses.

Reconstitution and storage

No CJC-1295 form is approved, so no official mixing or storage instructions exist; FDA relayed this vendor data in 2024:¹

• Appearance: the free base is described as a white freeze-dried (lyophilized) powder.¹
• Solubility: the free base is only slightly soluble in water but dissolves in 1% acetic acid, while the acetate is reported soluble in water at 5 mg/mL.¹
• Storage: the free base as a solid, 4 years or more at -20 °C; the acetate powder, up to 3 years at -20 °C; the acetate in solvent, up to 1 year at -80 °C.¹

No published study shows how long Mod GRF 1-29 stays stable after mixing, and FDA notes that peptides like it can be extremely sensitive to pH, heat, concentration, impurities and excipients, which can cause clumping (aggregation), breakdown and loss of activity.¹ Whether a water-based diluent such as bacteriostatic water dissolves a vial fully depends on its salt form, so check the lot's certificate of analysis, where one exists, before mixing. The Reconstitution calculator does the concentration math; How to reconstitute a peptide vial and How to store peptides cover the lab steps.

Regulatory status

United States

FDA has not approved CJC-1295 No DAC for any use; its 2024 review found no USP or NF monograph for any CJC-1295 form and no approved drug containing one.¹ Under section 503A, pharmacies may compound only with bulk substances that have such a monograph, are components of approved drugs, or appear on FDA's 503A bulks list.¹⁸ After the nominations were withdrawn, FDA evaluated five CJC-1295 substances on its own initiative and proposed listing none, and its advisory committee agreed on December 4, 2024: 13 to 0 against the free base, 12 to 1 against the acetate and 13 to 0 against each DAC form.¹³ As of October 2026, the only Federal Register document naming CJC-1295 is the 2024 notice of that meeting.¹⁹

FDA's page on bulk substances that may present significant safety risks, updated April 22, 2026, lists CJC-1295 among substances previously in category 2 whose nominations were withdrawn. It cites possible immune reactions, impurity and characterization problems, serious adverse events and limited clinical data.¹⁶

An April 1, 2020 warning letter told a Kentucky compounding pharmacy that drugs it made from substances including CJC 1295 were not eligible for the 503A exemptions.²⁰ In August 2026, FDA told an online peptide seller that "for laboratory, research, and analytical use" labels did not change its finding of intended human use, citing bacteriostatic water sold with a "peptide calculator".²¹ CJC-1295 was not on the agenda of FDA's July 2026 advisory meetings on peptides.²²

Other countries and sport

FDA found no approved CJC-1295 product in 12 countries it checked, including Australia, Canada, Japan and the UK, none authorized by the European Medicines Agency, and no entry in the European or Japanese pharmacopoeias.¹ WADA prohibits GHRH and its analogues under S2.2.4, naming CJC-1295; S2 substances are banned at all times on both the 2026 list and the 2027 list, in force from January 1, 2027.⁸²³ A 2026 urine test, validated to WADA guidelines, detects GHRH analogs including CJC-1295 at 0.5 ng/mL or lower.⁷